BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23557216)

  • 1. SOX7 is down-regulated in lung cancer.
    Hayano T; Garg M; Yin D; Sudo M; Kawamata N; Shi S; Chien W; Ding LW; Leong G; Mori S; Xie D; Tan P; Koeffler HP
    J Exp Clin Cancer Res; 2013 Apr; 32(1):17. PubMed ID: 23557216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-9 is involved in TGF-β1-induced lung cancer cell invasion and adhesion by targeting SOX7.
    Han L; Wang W; Ding W; Zhang L
    J Cell Mol Med; 2017 Sep; 21(9):2000-2008. PubMed ID: 28266181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of miR‑935 increases paclitaxel sensitivity via regulation of SOX7 in non‑small‑cell lung cancer.
    Peng B; Li C; Cai P; Yu L; Zhao B; Chen G
    Mol Med Rep; 2018 Sep; 18(3):3397-3402. PubMed ID: 30066948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling.
    Dasgupta S; Jang JS; Shao C; Mukhopadhyay ND; Sokhi UK; Das SK; Brait M; Talbot C; Yung RC; Begum S; Westra WH; Hoque MO; Yang P; Yi JE; Lam S; Gazdar AF; Fisher PB; Jen J; Sidransky D
    J Mol Med (Berl); 2013 Mar; 91(3):381-93. PubMed ID: 22968441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Classic SRY-box protein SOX7 functions as a tumor suppressor regulating WNT signaling and is methylated in renal cell carcinoma.
    Wang L; Fan Y; Zhang L; Li L; Kuang G; Luo C; Li C; Xiang T; Tao Q; Zhang Q; Ying J
    FASEB J; 2019 Jan; 33(1):254-263. PubMed ID: 29957056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 7. The regulation of SOX7 and its tumor suppressive role in breast cancer.
    Stovall DB; Wan M; Miller LD; Cao P; Maglic D; Zhang Q; Stampfer MR; Liu W; Xu J; Sui G
    Am J Pathol; 2013 Nov; 183(5):1645-1653. PubMed ID: 24012678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
    Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
    Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
    Watanabe S; Hayashi H; Haratani K; Shimizu S; Tanizaki J; Sakai K; Kawakami H; Yonesaka K; Tsurutani J; Togashi Y; Nishio K; Ito A; Nakagawa K
    Cancer Sci; 2019 Jan; 110(1):52-60. PubMed ID: 30390416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Krüppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells.
    Ito G; Uchiyama M; Kondo M; Mori S; Usami N; Maeda O; Kawabe T; Hasegawa Y; Shimokata K; Sekido Y
    Cancer Res; 2004 Jun; 64(11):3838-43. PubMed ID: 15172991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82.
    Yang CH; Chou HC; Fu YN; Yeh CL; Cheng HW; Chang IC; Liu KJ; Chang GC; Tsai TF; Tsai SF; Liu HP; Wu YC; Chen YT; Huang SF; Chen YR
    Biochim Biophys Acta; 2015 Jul; 1852(7):1540-9. PubMed ID: 25912735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer.
    Tang X; Yin X; Xiang T; Li H; Li F; Chen L; Ren G
    Cancer Biomark; 2012-2013; 12(1):11-9. PubMed ID: 23321465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
    Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/β-catenin signaling pathway.
    Liu H; Yan ZQ; Li B; Yin SY; Sun Q; Kou JJ; Ye D; Ferns K; Liu HY; Liu SL
    J Ovarian Res; 2014 Sep; 7():87. PubMed ID: 25297608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.
    Sunaga N; Imai H; Shimizu K; Shames DS; Kakegawa S; Girard L; Sato M; Kaira K; Ishizuka T; Gazdar AF; Minna JD; Mori M
    Int J Cancer; 2012 Apr; 130(8):1733-44. PubMed ID: 21544811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors.
    Kubo T; Yamamoto H; Lockwood WW; Valencia I; Soh J; Peyton M; Jida M; Otani H; Fujii T; Ouchida M; Takigawa N; Kiura K; Shimizu K; Date H; Minna JD; Varella-Garcia M; Lam WL; Gazdar AF; Toyooka S
    Int J Cancer; 2009 Apr; 124(8):1778-84. PubMed ID: 19117057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
    Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
    Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.
    Minakata K; Takahashi F; Nara T; Hashimoto M; Tajima K; Murakami A; Nurwidya F; Yae S; Koizumi F; Moriyama H; Seyama K; Nishio K; Takahashi K
    Cancer Sci; 2012 Nov; 103(11):1946-54. PubMed ID: 22863020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting SOX18 Transcription Factor Activity by Small-Molecule Inhibitor Sm4 in Non-Small Lung Cancer Cell Lines.
    Rodak O; Mrozowska M; Rusak A; Gomułkiewicz A; Piotrowska A; Olbromski M; Podhorska-Okołów M; Ugorski M; Dzięgiel P
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of SOX7 by DNA methylation and its tumor suppressor function in acute myeloid leukemia.
    Man CH; Fung TK; Wan H; Cher CY; Fan A; Ng N; Ho C; Wan TS; Tanaka T; So CW; Kwong YL; Leung AY
    Blood; 2015 Jun; 125(25):3928-36. PubMed ID: 25940713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.